Atracurium
Nondepolarizing Neuromuscular Blocker — MUSCULO-SKELETAL SYSTEM
Also known as: atracurium besylate, tracrium
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Atracurium is an ofp drug in the Nondepolarizing Neuromuscular Blocker class catalogued in DrugCentral. It was first approved by the FDA in 1983. DrugCentral lists 6 molecular targets, including CHRNA3, CHRNA7 and CHRNA4. Recorded indications include General anesthesia, Muscle relaxation, function and Skeletal Muscle Relaxation for Endotracheal Intubation.
- Approval status: ofp (first approved 1983 by the FDA).
- Drug class: Nondepolarizing Neuromuscular Blocker.
- Molecular targets: CHRNA3, CHRNA7, CHRNA4 and CHRNA1|CHRNB1|CHRND (6 listed in DrugCentral).
- Indications: General anesthesia, Muscle relaxation, function and Skeletal Muscle Relaxation for Endotracheal Intubation.
- ATC code: M03AC04 (Other quaternary ammonium compounds).
- Molecular formula: C53H72N2O12; molecular weight 929.16 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (3)
- General anesthesia
- Muscle relaxation, function
- Skeletal Muscle Relaxation for Endotracheal Intubation
Contraindications (10)
- Disorder of electrolytes
- Disorder of lung
- Eaton-Lambert syndrome
- Hypermagnesemia
- Hypocalcemia
- Hypokalemia
- Hypothermia
- Low blood pressure
- Malignant hyperthermia
- Myasthenia gravis
Mechanism & targets
| Established pharmacologic class | Nondepolarizing Neuromuscular Blocker |
|---|
Molecular targets (6)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Neuronal acetylcholine receptor subunit alpha-3 | CHRNA3 | antagonist | IC50 9.05 |
| Neuronal acetylcholine receptor subunit alpha-7 | CHRNA7 | antagonist | IC50 8.25 |
| Neuronal acetylcholine receptor subunit alpha-4 | CHRNA4 | antagonist | IC50 8.10 |
| Acetylcholine receptor | CHRNA1|CHRNB1|CHRND | antagonist | IC50 7.77 |
| Small conductance calcium-activated potassium channel protein 3 | Kcnn3 | unknown | Ki 5.23 |
| Neuronal acetylcholine receptor subunit alpha-2 | CHRNA2 | unknown | — |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1983-11-23 | FDA | — | — |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
M03AC04 | MUSCULO-SKELETAL SYSTEM › MUSCLE RELAXANTS › MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS › Other quaternary ammonium compounds |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Anaphylactic shock | 1572.5 |
| Anaphylactic reaction | 631.0 |
| Bronchospasm | 436.5 |
| Hypotension | 320.5 |
| Mental status changes postoperative | 222.6 |
| Cardiac arrest | 190.6 |
| Circulatory collapse | 130.6 |
| Eosinophilia | 117.1 |
| Wrong product administered | 106.6 |
| Bradycardia | 100.8 |
| Tachycardia | 98.2 |
| Rash maculo-papular | 93.3 |
Chemical structure
| Molecular formula | C53H72N2O12 |
|---|---|
| Molecular weight | 929.16 g/mol |
| CAS number | 64228-79-1 |
| InChIKey | YXSLJKQTIDHPOT-UHFFFAOYSA-N |
| PubChem CID | 47319 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Atracurium used for?
DrugCentral lists the following indications for Atracurium: General anesthesia, Muscle relaxation, function and Skeletal Muscle Relaxation for Endotracheal Intubation.
How does Atracurium work?
Its molecular targets in DrugCentral include CHRNA3 (antagonist), CHRNA7 (antagonist), CHRNA4 (antagonist) and CHRNA1|CHRNB1|CHRND (antagonist).
When was Atracurium first approved?
Atracurium was first approved by the FDA in 1983.
What drug class does Atracurium belong to?
Atracurium is in the Nondepolarizing Neuromuscular Blocker class.
What is the chemical formula of Atracurium?
Atracurium has the molecular formula C53H72N2O12 and a molecular weight of 929.16 g/mol.
Browse: all drugs starting with A · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 259 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1200527 — compound record and bioactivity
- PubChem CID 47319 — chemical identifiers
- DrugBank DB00732 — drug record
- FDA UNII 2GQ1IRY63P — substance identity
- DailyMed: FDA labels for Atracurium — current prescribing information (label search)
- UniProt P32297 (CHRNA3) — target protein
- UniProt P36544 (CHRNA7) — target protein
- UniProt P43681 (CHRNA4) — target protein
- UniProt Q15822 (CHRNA2) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.